These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37650266)

  • 1. Raman spectroscopy and U-Net deep neural network in antiresorptive drug-related osteonecrosis of the jaw.
    Matthies L; Gebrekidan MT; Braeuer AS; Friedrich RE; Stelzle F; Schmidt C; Smeets R; Assaf AT; Gosau M; Rolvien T; Knipfer C
    Oral Dis; 2024 May; 30(4):2439-2452. PubMed ID: 37650266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.
    Matthies L; Amir-Kabirian H; Gebrekidan MT; Braeuer AS; Speth US; Smeets R; Hagel C; Gosau M; Knipfer C; Friedrich RE
    PLoS One; 2024; 19(4):e0302017. PubMed ID: 38603731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
    Assaf AT; Amberg V; Smeets R; Wikner J; Hanken H; Semmusch J; Ewald F; Rashad A; Friedrich RE
    Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular alterations of bone quality in sequesters of bisphosphonates-related osteonecrosis of the jaws.
    Olejnik C; Falgayrac G; During A; Vieillard MH; Maes JM; Cortet B; Penel G
    Osteoporos Int; 2014 Feb; 25(2):747-56. PubMed ID: 24081510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
    Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
    Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
    J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
    Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T
    J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
    Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
    J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
    Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
    J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
    Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
    PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
    ; Yoneda T; Hagino H; Sugimoto T; Ohta H; Takahashi S; Soen S; Taguchi A; Nagata T; Urade M; Shibahara T; Toyosawa S
    J Bone Miner Metab; 2017 Jan; 35(1):6-19. PubMed ID: 28035494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
    Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
    Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis.
    Fujieda Y; Atsumi T
    J Bone Miner Metab; 2020 Sep; 38(5):739-741. PubMed ID: 32591907
    [No Abstract]   [Full Text] [Related]  

  • 17. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
    Nashi M; Hirai T; Iwamoto T; Takenobu T
    J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
    Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Urologic Cancers].
    Kawanishi H; Yokozeki H; Hoshiyama A; Watanabe H; Funahashi Y; Fujiwara M; Takashima Y; Shintani M; Yui S; Okumura K
    Hinyokika Kiyo; 2022 Jan; 68(1):1-6. PubMed ID: 35114759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.